title: Once-daily therapies.
abstract: Combination antiretroviral therapy is now standard treatment for HIV infection. However, adherence to these treatment regimens remains a formidable barrier, owing to their complex and demanding nature and the severity of the associated toxicities. As suboptimal adherence increases the risk of treatment failure, the need for simpler and safer regimens is imperative. A number of strategies have been used to simplify dosing regimens and reduce pill burdens. At present, several antiretroviral drugs can be used once daily, while others have demonstrated pharmacokinetic potential for once-daily dosing and a number of compounds are in clinical development. It is possible that in the future, once-daily dosing will become the standard.
authors.affiliation: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Darlinghurst NSW 2010, Australia. dcarey@nchecr.unsw.edu.au
authors.forename: Dianne
authors.initials: D
authors.lastname: Carey
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D010349:Patient Compliance; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D044966:Anti-Retroviral Agents; D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors